6LRA
The complex structure of PHF core domain peptide of tau and antibody's Fab domain.
6LRA の概要
| エントリーDOI | 10.2210/pdb6lra/pdb |
| 分子名称 | Fab Heavy Chain, Fab Light Chain, VQIINK, ... (4 entities in total) |
| 機能のキーワード | tauopathies, tau protein, antibody, alzheimer's disease, immune system |
| 由来する生物種 | Mus musculus 詳細 |
| タンパク質・核酸の鎖数 | 3 |
| 化学式量合計 | 47534.98 |
| 構造登録者 | Tomohiro, T.,Kouki, S.,Tomohiro, S.,Takahiro, T.,Katsushiro, M.,Yasuko, I.,Katsuhiko, M.,Taizo, T.,Toshimitsu, I.,Koji, T. (登録日: 2020-01-15, 公開日: 2020-08-26, 最終更新日: 2024-11-13) |
| 主引用文献 | Tsuchida, T.,Susa, K.,Kibiki, T.,Tsuchiya, T.,Miyamoto, K.,In, Y.,Minoura, K.,Taniguchi, T.,Ishida, T.,Tomoo, K. Crystal structure of the human tau PHF core domain VQIINK complexed with the Fab domain of monoclonal antibody Tau2r3. Febs Lett., 2020 Cited by PubMed Abstract: Neurofibrillary tangles formed by abnormally aggregated tau protein are a histopathological feature of tauopathies. A tau aggregation inhibitor is a potential therapeutic agent for tauopathies. In this study, we prepared a monoclonal antibody for tau, monoclonal antibody to tau protein (Tau2r3), using as epitope the GGKVQIINKKLD peptide in the microtubule-binding domain of tau, the key region mediating tau aggregation. We show that Tau2r3 clearly inhibits tau aggregation. To analyze the inhibition mechanism of Tau2r3, we solved the crystal structure of the Fab domain of Tau2r3 (Fab2r3) in complex with the VQIINK peptide. In the Fab2r3-VQIINK structure, the second and sixth polar residues and the fourth hydrophobic residue of VQIINK are crucial for binding to Fab2r3. The structural data for the Fab2r3-VQIINK complex could contribute to the design of new tau aggregation inhibitors. PubMed: 32282060DOI: 10.1002/1873-3468.13791 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.9 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






